Microglia News and Research

RSS

Transition commences dosing in TT-301 Phase 1 clinical study for rheumatoid arthritis, ICH, TBI

Transition Therapeutics Inc. announced today that the first patient has been dosed with drug candidate TT-301 in a Phase 1 clinical study. TT-301 is a small molecule compound that has demonstrated efficacy in preclinical models of rheumatoid arthritis, intracerebral haemorrhage and traumatic brain injury.

30 Jun 2010

New study provides cause-and-effect link between immune system cells and mental illness

A Nobel Prize-winning University of Utah geneticist discovered that bone marrow transplants cure mutant mice who pull out their hair compulsively. The study provides the first cause-and-effect link between immune system cells and mental illness, and points toward eventual new psychiatric treatments.

28 May 2010

Bone marrow transplant cures excessive pathological grooming behavior in mice

Scientists earlier found that mice missing one of a group of core developmental genes known as the Hox genes developed an odd and rather unexpected pathology: the mutant animals groomed themselves compulsively to the point that they were removing their own hair and leaving self-inflicted open sores on their skin. Now, they've found a surprising connection between the Hoxb8 gene and the behavior that looks an awful lot like that of people with an obsessive compulsive spectrum disorder (OCD).

28 May 2010

Resolvyx presents new data on RX-10001 for corneal herpes simplex virus infection at ARVO 2010

Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced the presentation of data on its novel resolvins for the treatment of both ocular surface diseases and retinal diseases at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Fort Lauderdale, Florida, being held May 2-6, 2010.

7 May 2010

Plexxikon presents promising preclinical data from PLX3397 in vivo cancer studies

Plexxikon Inc. today announced promising preclinical data from in vivo cancer studies with PLX3397 demonstrating significant reduction in tumor burden, metastatic spread, bone erosion and cancer bone pain. PLX3397 is an oral, selective kinase inhibitor that down-modulates macrophages, microglia, osteoclasts and mast cells, all cell types targeted by this drug candidate. These cell types play a key role in cancer and metastasis.

21 Apr 2010

Role of beta defensins in development of chronic inflammatory response in the brain

Researchers at the Case Western Reserve University School of Dental Medicine and School of Medicine will look for evidence within the brain for human beta defensin peptide function-proteins important to the peripheral body's natural defense system against infection from the outside environment.

8 Apr 2010

Microglia contribute to loss of neurons linked with Alzheimer's disease

Microglia are the cells responsible for immune surveillance in the brain, and they initiate protective inflammatory reactions in response to tissue damage and infection. An international team under the leadership of LMU neuroscientist Professor Jochen Herms has now shown that these cells may actually make a significant contribution to the loss of neurons associated with Alzheimer's disease.

22 Mar 2010

Scientists anticipate new approaches in drug development to combat prion infection

The regulating protein Srebp2 drives cholesterol formation, which prions need for their propagation, in prion-infected neuronal cells. With these findings, published in the current issue of the Journal of Biological Chemistry, scientists of Helmholtz Zentrum München and Technische Universität München anticipate new approaches in drug development to combat prion infection.

20 Nov 2009

Molecular imaging pinpoints inflammation in the brains of schizophrenics and migraine sufferers

Inflammatory response of brain cells-as indicated by a molecular imaging technique-could tell researchers more about why certain neurologic disorders, such as migraine headaches and psychosis in schizophrenic patients, occur and provide insight into how to best treat them, according to two studies published in the November issue of the Journal of Nuclear Medicine.

31 Oct 2009

APC enzyme may be effective for treating amyotrophic lateral sclerosis

A chemical cousin of a drug currently used to treat sepsis dramatically slows the progression of amyotrophic lateral sclerosis, better known as ALS or Lou Gehrig's disease, in mice. The results offer a bit of good news in efforts to develop a therapy to stop or slow the progression of a disease that generally kills its victims within just a few years.

26 Oct 2009

University researchers inject 'nanowires' in rat brains

The biological safety of nanotechnology, in other words, how the body reacts to nanoparticles, is a hot topic. Researchers at Lund University in Sweden have managed for the first time to carry out successful experiments involving the injection of so-called 'nanowires.'

23 Oct 2009

Brain inflammation not linked to Alzheimer's disease

In a surprising reversal of long-standing scientific belief, researchers at the Mayo Clinic campus in Florida have discovered that inflammation in the brain is not the trigger that leads to buildup of amyloid deposits and development of Alzheimer's disease.

23 Oct 2009

Breakthrough discovery by scientists may lead to a new treatment for Alzheimer's Disease

A breakthrough discovery by scientists from the Mayo Clinic in Jacksonville, FL, may lead to a new treatment for Alzheimer's Disease that actually removes amyloid plaques-considered a hallmark of the disease-from patients' brains.

19 Oct 2009

MRF announces winners of six 2009 research grants

The Migraine Research Foundation (MRF), the only nonprofit organization devoted solely to funding migraine research, today announced the winners of the 2009 research grants. This year's grantees will explore such important areas as pediatric migraine, the genetic association between migraine and cardiovascular events, and why opioids enhance migraine pain.

5 Sep 2009

Biogen Idec's MS franchise to present at the 25th Congress of ECTRIMS

Biogen Idec today announced more than 70 platform and poster presentations from the company’s multiple sclerosis (MS) franchise being presented during the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Düsseldorf, Germany.

3 Sep 2009

Cytrx’s study offers a better perception of arimoclomol's mechanism of action in induced animal stroke

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that study results demonstrated that arimoclomol exhibited both statistically significant neuroprotective and neuroregenerative effects in brain cells of animals induced with stroke, offering important insights into this drug candidate’s mechanism of action.

25 Aug 2009

Compound from coral offers hope fpr neuropathic pain

A compound initially isolated from a soft coral (Capnella imbricata) collected at Green Island off Taiwan, could lead scientists to develop a new set of treatments for neuropathic pain - chronic pain that sometimes follows damage to the nervous system.

4 Aug 2009

Direct link found between smoking and brain damage

New research which suggests a direct link between smoking and brain damage will be published in the July issue of the Journal of Neurochemistry. Researchers, led by Debapriya Ghosh and Dr Anirban Basu from the Indian National Brain Research Center (NBRC), have found that a compound in tobacco provokes white blood cells in the central nervous system to attack healthy cells, leading to severe neurological damage.

23 Jun 2009

Inflammation of microglia may not be associated with dementia in Alzheimer's disease

The idea that anti-inflammatory drugs might protect people struggling with dementia from Alzheimer's disease has received a blow with the online release of a study of human brain tissue in Acta Neuropathologica.

15 Jun 2009

oct3 protein key to Parkinson's, drug addiction

Scientists have identified a protein that appears not only to be central to the process that causes Parkinson's disease but could also play a role in muting the high from methamphetamine and other addictive drugs.

4 May 2009